
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus is supported by a resilient core franchise in HA injections, bone graft substitutes, and fracture care, with Durolane showing rapid growth since its U.S. launch in 2018 and a leading position in single-injection pain treatment. Management also believes BGS can outgrow a low-single-digit market and that fracture care remains durable despite reimbursement pressure, while the company generated over $72 million in free cash flow in 2025, up from less than $38 million in 2024. The outlook is further strengthened by investments of about $13 million in 2026 across PNS, PRP, ultrasonics, and international, alongside +7.5% organic revenue growth in FY25, expanding adj. EBITDA margins above 20% in 2025, and continued debt reduction that should improve capital allocation flexibility.
Bears say
Bioventus is challenged by intense competition in spinal fusion and related musculoskeletal markets, where larger, better-capitalized rivals like Johnson & Johnson and Medtronic have broader product portfolios and stronger ability to win share. Its outlook is further pressured by dependence on FDA and other regulatory approvals, because delays or remediation can be costly and time-consuming, while reimbursement risk in the U.S. and abroad can reduce procedure volumes and pricing flexibility. The company’s acquisition-heavy strategy adds integration, execution, and potential dilution risk, and its efforts to expand the commercial network may not translate into sustainable productivity or financial improvement.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Bioventus (BVS) Forecast
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares